ES2166778T3 - Factor de crecimiento ii de tipo insulina como agente antitumoral. - Google Patents
Factor de crecimiento ii de tipo insulina como agente antitumoral.Info
- Publication number
- ES2166778T3 ES2166778T3 ES94915218T ES94915218T ES2166778T3 ES 2166778 T3 ES2166778 T3 ES 2166778T3 ES 94915218 T ES94915218 T ES 94915218T ES 94915218 T ES94915218 T ES 94915218T ES 2166778 T3 ES2166778 T3 ES 2166778T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- growth factor
- insulin type
- medicament
- antitumoral agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030381 cutaneous melanoma Diseases 0.000 abstract 1
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000003708 skin melanoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCION SE REFIERE AL USO DE IGF-II PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TUMORES, Y ESPECIALMENTE PARA LA FABRICACION DE UN MEDICAMENTO PARA LA INHIBICION DEL CRECIMIENTO DE LAS CELULAS DEL MELANOMA Y PARA EL TRATAMIENTO DE MELANOMAS CUTANEOS. EL MEDICAMENTO PUEDE SER ADMINISTRADO SISTEMATICAMENTE O LOCALMENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939310049A GB9310049D0 (en) | 1993-05-12 | 1993-05-12 | Growth factor effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2166778T3 true ES2166778T3 (es) | 2002-05-01 |
Family
ID=10735556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94915218T Expired - Lifetime ES2166778T3 (es) | 1993-05-12 | 1994-05-12 | Factor de crecimiento ii de tipo insulina como agente antitumoral. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5902788A (es) |
| EP (1) | EP0697885B1 (es) |
| JP (1) | JPH08510230A (es) |
| AT (1) | ATE205398T1 (es) |
| AU (1) | AU682862B2 (es) |
| CA (1) | CA2162594A1 (es) |
| DE (1) | DE69428276T2 (es) |
| DK (1) | DK0697885T3 (es) |
| ES (1) | ES2166778T3 (es) |
| GB (1) | GB9310049D0 (es) |
| NZ (1) | NZ265994A (es) |
| PT (1) | PT697885E (es) |
| WO (1) | WO1994026300A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630168B1 (en) | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2507106B2 (ja) * | 1987-12-24 | 1996-06-12 | グロペップ プロプライエタリー リミテッド | インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド |
| SE9101341D0 (sv) * | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | New medicinal use |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
-
1993
- 1993-05-12 GB GB939310049A patent/GB9310049D0/en active Pending
-
1994
- 1994-05-12 ES ES94915218T patent/ES2166778T3/es not_active Expired - Lifetime
- 1994-05-12 AU AU66547/94A patent/AU682862B2/en not_active Ceased
- 1994-05-12 DE DE69428276T patent/DE69428276T2/de not_active Expired - Fee Related
- 1994-05-12 WO PCT/GB1994/001030 patent/WO1994026300A1/en not_active Ceased
- 1994-05-12 JP JP6525163A patent/JPH08510230A/ja active Pending
- 1994-05-12 AT AT94915218T patent/ATE205398T1/de not_active IP Right Cessation
- 1994-05-12 EP EP94915218A patent/EP0697885B1/en not_active Expired - Lifetime
- 1994-05-12 US US08/549,676 patent/US5902788A/en not_active Expired - Fee Related
- 1994-05-12 PT PT94915218T patent/PT697885E/pt unknown
- 1994-05-12 NZ NZ265994A patent/NZ265994A/en unknown
- 1994-05-12 DK DK94915218T patent/DK0697885T3/da active
- 1994-05-12 CA CA002162594A patent/CA2162594A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB9310049D0 (en) | 1993-06-30 |
| ATE205398T1 (de) | 2001-09-15 |
| US5902788A (en) | 1999-05-11 |
| NZ265994A (en) | 2001-02-23 |
| CA2162594A1 (en) | 1994-11-24 |
| AU6654794A (en) | 1994-12-12 |
| DE69428276D1 (de) | 2001-10-18 |
| AU682862B2 (en) | 1997-10-23 |
| JPH08510230A (ja) | 1996-10-29 |
| WO1994026300A1 (en) | 1994-11-24 |
| PT697885E (pt) | 2002-03-28 |
| DK0697885T3 (da) | 2001-12-31 |
| EP0697885A1 (en) | 1996-02-28 |
| DE69428276T2 (de) | 2002-05-16 |
| EP0697885B1 (en) | 2001-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003960A (es) | Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos. | |
| FI956014A0 (fi) | Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon | |
| NO20101190L (no) | Anvendelse av buprenorfin i fremstillingen av et medikament | |
| CO4290346A1 (es) | Formas de dosificacion de liberacion controlada de azitromicina | |
| SE9702860D0 (sv) | New use | |
| PT671910E (pt) | Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma | |
| ES2156839T1 (es) | Medicamento que contiene alginato e implante para tratar la fibrosis. | |
| PT1161248E (pt) | Composição farmacêutica que contém uma fonte de nitrato e um agente acidificante destinada ao tratamento de feridas abertas e queimaduras | |
| DE60143911D1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| DE69905368D1 (en) | Oxydiertes thymosin beta 4 | |
| GR3024787T3 (en) | Levobupivacaine useful for managing chronic pain | |
| EP0902789A4 (es) | ||
| BG106171A (en) | Compositions and uses of et743 for treating cancer | |
| BG106057A (en) | Method of enhancing the efficacy of anti-tumour agents | |
| SE9701161D0 (sv) | New use I | |
| DE60044674D1 (de) | Verwendung von rhamnolipiden zur wundheilung, behaund periodontaler regeneration | |
| AU1795101A (en) | Safety mechanism to prevent accidental patient injection and methods of same | |
| DE69821498D1 (de) | Verwendung von amifostin | |
| GB0020504D0 (en) | Therapeutic method | |
| ES2068714T3 (es) | Derivados de pirimidina para aumentar la actividad antitumoral. | |
| GEP20043231B (en) | Resorcinol Composition | |
| AU6432899A (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
| DE69428276D1 (de) | Insulinähnlicher wachstumfaktor ii als antitumormittel | |
| ATE293983T1 (de) | Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie | |
| ES2110104T3 (es) | Procedimiento para la administracion de soluciones de factor de estimulacion de las colonias de granulocitos. |